A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
Feng Jin,1,2 Hui Zhu,1,2 Fang Shi,1,2 Li Kong,1,2 Jinming Yu1,21Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 2Shandong Academy of Medical Sciences, University of Jinan, Jinan, Shandong Province, People’s Republic of ChinaPurpose: The aim of this retrospective s...
Guardado en:
Autores principales: | Jin F, Zhu H, Shi F, Kong L, Yu J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/af533ff75ea44d7e8f41bb41d50639de |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas M, et al.
Publicado: (2017) -
Nab-paclitaxel-associated photosensitivity: report in a woman with non-small cell lung cancer and review of taxane-related photodermatoses
por: Bryce D. Beutler, et al.
Publicado: (2015) -
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Yizhao Xie, et al.
Publicado: (2021) -
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Tobias Dechow, et al.
Publicado: (2021) -
Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
por: You-Yi Chen, et al.
Publicado: (2021)